Biswas Mohitosh, Rahaman Shawonur, Biswas Tapash Kumar, Haque Zahirul, Ibrahim Baharudin
Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh,
Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.
Intervirology. 2020 Dec 9:1-12. doi: 10.1159/000512592.
Although severe acute respiratory syndrome coronavirus-2 infection is causing mortality in considerable proportion of coronavirus disease-2019 (COVID-19) patients, however, evidence for the association of sex, age, and comorbidities on the risk of mortality is not well-aggregated yet. It was aimed to assess the association of sex, age, and comorbidities with mortality in COVID-2019 patients.
Literatures were searched using different keywords in various databases. Relative risks (RRs) were calculated by RevMan software where statistical significance was set as p < 0.05.
COVID-19 male patients were associated with significantly increased risk of mortality compared to females (RR 1.86: 95% confidence interval [CI] 1.67-2.07; p < 0.00001). Patients with age ≥50 years were associated with 15.4-folds significantly increased risk of mortality compared to patients with age <50 years (RR 15.44: 95% CI 13.02-18.31; p < 0.00001). Comorbidities were also associated with significantly increased risk of mortality; kidney disease (RR 4.90: 95% CI 3.04-7.88; p < 0.00001), cereborovascular disease (RR 4.78; 95% CI 3.39-6.76; p < 0.00001), cardiovascular disease (RR 3.05: 95% CI 2.20-4.25; p < 0.00001), respiratory disease (RR 2.74: 95% CI 2.04-3.67; p < 0.00001), diabetes (RR 1.97: 95% CI 1.48-2.64; p < 0.00001), hypertension (RR 1.95: 95% CI 1.58-2.40; p < 0.00001), and cancer (RR 1.89; 95% CI 1.25-2.84; p = 0.002) but not liver disease (RR 1.64: 95% CI 0.82-3.28; p= 0.16).
Implementation of adequate protection and interventions for COVID-19 patients in general and in particular male patients with age ≥50 years having comorbidities may significantly reduce risk of mortality associated with COVID-19.
尽管严重急性呼吸综合征冠状病毒2感染在相当一部分2019冠状病毒病(COVID-19)患者中导致死亡,但关于性别、年龄和合并症与死亡风险之间关联的证据尚未得到充分汇总。本研究旨在评估COVID-19患者的性别、年龄和合并症与死亡之间的关联。
在多个数据库中使用不同关键词进行文献检索。通过RevMan软件计算相对风险(RRs),设定统计学显著性为p<0.05。
与女性相比,COVID-19男性患者的死亡风险显著增加(RR 1.86:95%置信区间[CI] 1.67 - 2.07;p<0.00001)。与年龄<50岁的患者相比,年龄≥50岁的患者死亡风险显著增加15.4倍(RR 15.44:95% CI 13.02 - 18.31;p<0.00001)。合并症也与死亡风险显著增加相关;肾脏疾病(RR 4.90:95% CI 3.04 - 7.88;p<0.00001)、脑血管疾病(RR 4.78;95% CI 3.39 - 6.76;p<0.00001)、心血管疾病(RR 3.05:95% CI 2.20 - 4.25;p<0.00001)、呼吸系统疾病(RR 2.74:95% CI 2.04 - 3.67;p<0.00001)、糖尿病(RR 1.97:95% CI 1.48 - 2.64;p<0.00001)、高血压(RR 1.95:95% CI 1.58 - 2.40;p<0.00001)和癌症(RR 1.89;95% CI 1.25 - 2.84;p = 0.002),但不包括肝脏疾病(RR 1.64:95% CI 0.82 - 3.28;p = 0.16)。
对一般COVID-19患者,特别是对年龄≥50岁且有合并症的男性患者实施充分的保护和干预措施,可能会显著降低与COVID-19相关的死亡风险。